aphranel® MagiCCrystal Officially Launches Globally, Marking a New Era for China’s Regenerative Aesthetics Industry
China’s First Certification, Global Debut
May 8, 2025 · Shanghai, China
On May 8, 2025, Shanghai Moyom Biotechnology officially unveiled Aphranel® MagiCCrystal (Injectable Calcium Hydroxyapatite Microsphere Facial Filler) at its global launch event held at the Shanghai World Reception Hall.
Earlier in February 2025, Aphranel® received China’s NMPa Class III Medical Device Certification for medical aesthetic indications (Registration No. 20253130390), becoming one of the first approved regenerative CaHa injectable products in China’s medical aesthetics industry.
The global debut of Aphranel® not only marked the international launch of a Chinese-developed regenerative injectable material, but also represented a significant milestone for China’s aesthetics industry as it entered a new stage of innovation, regulation, and global competitiveness.
Chinese-Developed CaHa Technology
Advancing a New Generation of Regenerative aesthetics
Aphranel® MagiCCrystal is a regenerative CaHa-based injectable filler designed for facial structural support, contour enhancement, and collagen regeneration.
Powered by proprietary ACD-MT™ raspberry-shaped porous microsphere technology and the PCD-ETT™ physically cross-linked gel system, Aphranel is engineered to support structural integration, controlled degradation, and long-term collagen regeneration through precise microsphere and pore-structure design.
Built upon years of independent research and development, Aphranel® represents China’s transition from following global trends to developing internationally competitive regenerative aesthetic technologies.
At the time of launch, Aphranel® had already obtained EU MD certification, MDSaP certification, and Mexico COFEPRIS approval, becoming one of the first Chinese regenerative aesthetics brands simultaneously entering asian, European, and Latin american markets.
Global Recognition
International Experts Witness Chinese Aesthetic Innovation
During the launch event, Mr. Lin Guangming, Founder and Chairman of Moyom Biotechnology, reflected on Aphranel’s long-term journey from laboratory research to clinical application.
He emphasized:
“The launch of Aphranel is not only the debut of a product, but also a reflection of China’s growing capabilities in regenerative medical aesthetics, scientific innovation, and clinical development.”
Leading experts from China, Germany, and international medical aesthetics organizations attended the event and delivered keynote speeches on the future of regenerative aesthetics and structural anti-aging.
International experts also noted that Aphranel’s globalization represents not only commercial expansion, but also a new Chinese approach to controlled degradation, regenerative medicine, and precision anti-aging.
a symbolic butterfly ceremony was unveiled during the evening event, representing transformation, regeneration, and Aphranel’s vision for the future of global aesthetics.
Industry Empowerment
Building the Future Regenerative Aesthetics Ecosystem
Alongside the launch event, Aphranel hosted a regenerative aesthetics roundtable forum centered around the theme:
“Returning Medical Aesthetics to Its Medical Foundation”
Experts and industry leaders discussed the future of regenerative aesthetics from the perspectives of safety, structural science, long-term outcomes, and global clinical trends.
Participants shared the view that regenerative aesthetics is moving toward a future defined by precision, personalization, safety, and long-term structural harmony.
During the event, Aphranel also presented strategic partnership certifications to its first group of clinical partner institutions, marking the beginning of deeper collaboration across physician education, clinical application, and patient experience.
Chinese Innovation on the Global Stage
Opening a New Chapter in Regenerative Aesthetics
Looking ahead, Moyom Biotechnology will continue advancing the globalization of Chinese regenerative aesthetic materials while exploring deeper integration between medicine, aesthetics, and culture.
The company also announced future initiatives related to Eastern aesthetics and structural beauty concepts, aiming to establish a long-term dialogue between regenerative medicine and global aesthetic culture.
“The global debut of Aphranel is only the beginning,” said Mr. Lin Guangming.
“We hope Chinese regenerative technology can bring safer, more natural, and more sustainable aesthetic solutions to the global market — and allow the world to see the strength of Chinese innovation.”
